Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [19]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationSherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Research works printed but not linked: 7
- de la Tour, 2001, Mol. Endocrinol., 15, 476
- Boushey, 2001, Cancer Res., 61, 687
- Trumper, 2001, Mol. Endocrinol., 15, 1559
- Drucker, 1997, Am. J. Physiol., 273, G1252
- Drucker, 2001, J. Clin. Endocrinol. Metab., 86, 1759
- Bregenholt, 2001, 50, 125
- Sherwood, 2000, Endocr. Rev., 21, 619
Cited by
Items 501–597 of 597
Ramadan, O., Damanhory, A. A., Allah, E. E.-D. A., Gomah, T. A., Mahmoud, M. E., Abd-Allah, F. M., Sewilam, H. M., Fayyad, R. M. A., Darwish, M., Hashem, F. A., et al. (2024) · Journal of Research in Pharmacy · doi:10.29228/jrp.811 · Cited by 4
“…cells were damaged by a spontaneous autoimmune reaction that resulted in a condition similar to type 1 diabetes following treatment with vildagliptin {glucagon-like peptide-1 (GLP-1)} these improvements occurred due to elevated levels of GLP-1 as a result of DPP-4 inhibition of vildagliptin [32].”
BackgroundBetagenin ameliorates diabetes by inducing insulin secretion and β-cell proliferation
Yokoo, T., Watanabe, K., Iida, K., Nakachi, Y., Suzuki, H., Shimano, H., Takashima, S., Okazaki, Y., Yamada, N., & Toyoshima, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108202 · Cited by 3
Insulin-Producing Cells Derived from Embryonic Stem Cells: A Potential Treatment for Diabetes
Weir, G. C., Haagensen, A. L., & Bonner‐Weir, S. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50080-8 · Cited by 2
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00034-2 · Cited by 2
Self-citationBiological activity studies of the novel glucagon-like peptide-1 derivative HJ07
Han, J. D. J., Sun, L., Qian, H., & Huang, W. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60093-5 · Cited by 2
Bokvist, K. B., Ding, Y., Landschulz, W. H., Sinha, V. P., Pastrak, A., & Belin, R. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13695 · Cited by 2
Tissue engineering a pancreatic substitute based on recombinant intestinal endocrine cells
Bara, H. (2008) · SMARTech Repository (Georgia Institute of Technology) · Cited by 2
Valdez, C. A. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.7.650 · Cited by 2
Using Forced Degradation to Aid the Development of Biopharmaceutical Products
Benet, A. (2021) · Deep Blue (University of Michigan) · doi:10.7302/2763 · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
Clinical Approaches to Preserving β-Cell Function in Diabetes
WAJCHENBERG, B. L., & de Carvalho, R. M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_17 · Cited by 1
Arble, D. M., Hutch, C. R., Hafner, H., Stelmak, D., Leix, K., Sorrell, J. E., Pressler, J. W., Gregg, B. E., & Sandoval, D. A. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00152.2022 · Cited by 1
Erbasan, E., Aliciaslan, M., Erendor, F., Şensoy, S., Cetin, B., Aydemir, M., & Şanlıoğlu, S. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02690-w · Cited by 1
Molecular Biology of Gluco-Incretin Function
Klinger, S., & Thorens, B. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_16 · Cited by 1
Araújo-Filho, I., do Rêgo, A. C. M., Azevedo, Í. M., Carvalho, M. D. F., & Medeiros, A. C. (2013) · Journal of Investigative Surgery · doi:10.3109/08941939.2013.870622 · Cited by 1
Massoud, A. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-39495-9_3 · Cited by 1
César Hidalgo, P., María Vásquez, C., Boris Lira, M., & José Rodríguez, G. (2015) · Revista de Investigaciones Veterinarias del Perú · doi:10.15381/rivep.v26i3.11172 · Cited by 2
Tang, W., Yuan, Q., Xu, B., Osei, K., & Wang, J. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.09.015 · Cited by 1
“…ER stress and apoptosis, and stimulate beta-cell 118 proliferation and neogenesis (Gromada et al., 1998; Holz et al., 1999; Xu et al., 1999; Tourrel et al.,119 2001; Wang and Brubaker, 2002; Li et al., 2003; Gromada et al., 2004; Drucker, 2006; Tsunekawa et 120 al., 2007; Parkes et al., 2013).”
BackgroundPharmacology of the GLP-1 analog exenatide extended-release in healthy cats
Rudinsky, A. J. (2015) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Beta Cell Transplantation and Regeneration
Weir, G. C., & Gaglia, J. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00050-0 · Cited by 1
Molecular Basis of cAMP Signaling in Pancreatic Beta Cells
Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_25-3 · Cited by 1
VATSAVAYI, J. R., & REVU, B. N. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53379 · Cited by 1
Kheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1
Insulin Resistance, Diabetes and its Complications
Ng, D. S. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400011
Advances in the Treatment of Type 2 Diabetes and Cardiovascular Disease
Pi-Sunyer, X. (2008) · Revista Española de Cardiología
The activation of the glucagon-like peptide-1 (GLP-1) receptor by peptide and non-peptide ligands
Wishart, C. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Improving Insulin Sensitivity: A Review of New Therapies
Rhee, M. K., & Umpierrez, G. E. (2008) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60023-5 · Cited by 1
Drucker, D. J. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.112127
Self-citationPreclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin
Ito, H., Wajima, T., Yamaguchi, M., Mimori, N., & Sekiguchi, K. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.299
Vildagliptin Improves Glucose Tolerance and Decreases Plasma Triglycerides in Sprague-Dawley Rats
Koizumi, G., Kumai, T., Oda, G., Ohba, K., Tomoyori, E., Tokudome, T., Kawaguchi, K., Watanabe, M., Iwai, S., Matsumoto, N., et al. (2013) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms.25.213
Role of GLP-1 receptor agonists in endothelial function
Erdogdu, Ö. (2012) · Figshare
GLP 1 : effets biologiques et utilisation thérapeutique
Fagour, C. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.01.017
Andréasson, S. (2015) · Epsilon Archive for Student Projects (Swedish University of Agricultural Sciences)
Kaestner, K. H., Stoffers, D. A., León, D. D. D., Farzad, C., Crutchlow, M. F., & Brestelli, J. E. (2015)
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., & Costi, B. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_30
Holz, G. G., & Chepurny, O. G. (2005)
Nigris, V. D. (2015) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus
Mansur, S. A. (2015) · UTHM Institutional Repository (Universiti Tun Hussein Onn Malaysia)
Can drugs used in type 2 diabetes therapy induce acute pancreatitis?
Borowik, A., Hrycek, A., Chudek, J. T., & Olszanecka‐Glinianowicz, M. (2011) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.964936
Glucagon-like peptide-1 receptor: a novel therapeutic target for diabetes
Cai-hong, Z., Hu, H. Z., & Wang, M. (2004)
The Role of Incretins in Insulin Secretion
Salehi, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_4-1
Glucagon like peptide-1 (glp-1) in myocardial ischaemia-reperfusion injury.
Bose, A. (2006) · OpenGrey (Institut de l'Information Scientifique et Technique)
Treatment Patterns in Youth with Diabetes
Chiu, H., & Pihoker, C. (2008) · CRC Press eBooks · doi:10.3109/9781420047981-20
Pancreatic B -Cell, a Unique Fuel Sensor
Komatsu, M. (2005) · Oxidative stress and disease · doi:10.1201/9781420028362.pt3
Metabolic Syndrome and the Liver
Yoshiji, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55790-6_8
“GLP-1, a prominent active compound of the incretin family, is a gut-derived peptide secreted in a nutrient-dependent manner from the small intestine and stimulates glucosedependent insulin production and secretion via specific receptors expressed on the islet β cells [201–204].”
BackgroundLim, G. E. (2010) · TSpace (University of Toronto) · Cited by 1
Metabolic Actions of Glucagon-Like Peptides
Wideman, R. D., & Kieffer, T. J. (2005) · Oxidative stress and disease · doi:10.1201/9781420028362.ch19
Clinical Approaches to Preserving b-Cell Function in Diabetes 33
WAJCHENBERG, B. L., & de Carvalho, R. M. (2015) · Cited by 1
Wilson, H. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Energy Homeostasis During Fasting and Fed States: Foxa2 Regulates Hepatic Amino Acid Uptake
Lee, V. M. (2007) · Digital Commons - RU (Rockefeller University) · doi:10.48496/em89-nh27
The preproglucagon derived peptides and energy homeostasis
Parker, J. (2013) · doi:10.25560/10956
GI Peptides, Energy Balance, and Cancer
Bruno, D. S., & Wolfe, M. M. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41677-9_11
Therapeutic potential of GLP-1 for treatment of diabetes
Meenakshi, & Kumar, A. N. (2015) · International journal of applied research
Bahrami, J. (2011) · TSpace (University of Toronto)
Novel Enteroendocrine Cell Receptors Regulating Incretin Secretion and Glucose Homeostasis
Flock, G. B. (2012) · TSpace (University of Toronto)
de Sousa, L. R., Filho, A. A. R., Azevedo, Í. M., Carvalho, M. D. F., & Cunha, A. (2011)
Regulation of pancreatic beta-cell function by the renin-angiotensin system in type 2 diabetes
Shoemaker, R. (2015) · UKnowledge (University of Kentucky)
Bilasy, S. E. (2014) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2014.6955
Peptides come to the rescue of pancreatic β cells
Spiering, M. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.cl119.010307
“An article published in the Journal of Biological Chemistry (4), recognized as a Classic here, added to our understanding of the incretin effect by showing that GLP-1R signaling protects cells from cell death (Fig.”
BackgroundInsulin sensitivity is mediated by glucose in the hepatoportal region in the rat
Johnson, H. M. (2017) · The Sydney eScholarship Repository (The University of Sydney)
Farr, S. (2017) · TSpace (University of Toronto)
Pancreatic and Islet Transplantation
Weir, G. C., & Gaglia, J. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00050-2
Artificial sweeteners negatively impact gut epithelium and microflora
Shil, A. (2020) · Anglia Ruskin Research Online (Anglia Ruskin University)
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
The Relationship Between the Insulin Receptor Substrates and Metabolic Disease
White, M. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_14
Transcriptional regulation of healthy and diabetic pancreatic beta-cell gene expression
Ghanaat‐Pour, H. (2008) · Figshare
The Role of Incretins in Insulin Secretion
Salehi, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_4
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00035-6
Self-citationClinical Approaches to Preserving β-Cell Function in Diabetes
WAJCHENBERG, B. L., & de Carvalho, R. M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_17-3
GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes
Bandeira, F. A. F., Moura, F., Costi, B. B., & Cardoso, A. C. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_31
VATSAVAYI, J. R., & Nalanda, R. B. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i9.55110
Betagenin: New intestine‐derived hormone which ameliorates diabetes
Kim, Y. K., & Won, K. C. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70167
Juang, J., Chen, C.-Y., Kao, C.-W., Chen, C.-L., & Li, W. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/5847576
Duarte, A. G. T., do Nascimento, J. W. G., Silva, E. L. E. D. S., Corá, L. A., & Reis, M. D. D. S. (2025) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2025240485
Barry, M. (2013) · University of Brighton Repository (University of Brighton)
Gastrointestinale Hormonsysteme und ihre Regulation
Göke, B., de Heer, J., & Göke, R. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_11
Louzada, R. A. N., Medina, M. G., Pita-Grisanti, V., Blandino-Rosano, M., Crowley, L. A., Cui, T., Sha, W., Cai, R., Wangpaichitr, M., & Bernal‐Mizrachi, E. (2026) · Endocrinology · doi:10.1210/endocr/bqag104
VATSAVAYI, J. R., & Nalanda, R. B. (2026) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2026v19i1.56485
Myocardial ischemia reperfusion in diabetes: mechanism of injury and its drug treatment
Duan, P., Li, H. X., Li, J. H., Xing, L. P., Liu, A. N., Wang, C. H., & Fei, K. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02098-z
Piccand, J. (2012) · theses.fr (ABES) · doi:10.70675/9f80f37azfaacz4e60z8cd8zd178cf6a58ac
Contrôle de la masse fonctionnelle des cellules β pancréatiques par les glucocorticoïdes et pgc-1α
Besseiche, A. (2015) · theses.fr (ABES) · doi:10.70675/f16ecd6fza687z4a5fzac34zc26774dc9c3f
Bassil, F. (2015) · theses.fr (ABES) · doi:10.70675/3fdfc6e8z0aecz4d06zb54ezdff578cdc2b5
Lipopolysaccharides et glucagon-like peptide 1 : des mécanismes moléculaires à la physiopathologie
Lebrun, L. (2016) · theses.fr (ABES) · doi:10.70675/2a6e27b7zd640z4026z814fzdc6a27d73fed
Rôle des anses intestinales dans les effets métaboliques du gastric bypass : apport du modèle porcin
Marciniak, C. (2021) · theses.fr (ABES) · doi:10.70675/20ef750cz9657z4a87z8af5zc19b622f8793
Carré, A. (2022) · theses.fr (ABES) · doi:10.70675/28c85b2dz490az44c1zbbc4z061ea62b1e33
VATSAVAYI, J. R., & Nalanda, R. B. (2026) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2026v19i4.58313
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
Han, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
“It enhances glucose-stimulated insulin secretion by inducing insulin gene expression and promoting pancreatic beta-cell proliferation (Edvell and Lindström 1999; Buteau et al. 1999; Li et al. 2003).”
Metadata
- Authors
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 1
- Pages
- 471-478
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149502431
- Cited by
- 589
- References
- 64
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 26 · 2015: 34 · 2014: 41 · 2013: 45 · 2012: 33
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- GLP-1 receptor, beta-cell apoptosis, exendin-4, streptozotocin, beta-cell mass, cytokine-induced apoptosis, IL-1β, TNF-α, interferon-gamma, caspase activity, GLP-1 receptor signaling, type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Cell Survival, Cycloheximide, Cytoskeletal Proteins, Diabetes Mellitus, Experimental, Colforsin, Glucagon, Glucose Tolerance Test, Cricetinae, Insulin, Islets of Langerhans, Male, Mice, Inbred C57BL, Peptide Fragments, Peptides, Protein Precursors, Protein Synthesis Inhibitors, Streptozocin, Venoms, Signal Transduction, Trans-Activators, Cytokines, Rats, Wistar, Apoptosis, Receptors, Glucagon, Mice, Knockout, In Situ Nick-End Labeling, beta Catenin, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.